On March 1, 2023 BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, reported Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present an overview of the Company’s anticipated first in human clinical candidate, BSB-1001, and its discovery using the TCXpress platform at the Next Generation CAR & T Cell Therapies Conference held in San Diego, CA from February 27 – March 3, 2023 (Press release, BlueSphere Bio, MAR 1, 2023, View Source [SID1234627972]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BSB-1001, targeting the minor histocompatibility antigen-1 (HA-1) and part of BlueSphere’s TCX-101 Program, is the first TCR-based clinical candidate generated using TCXpress and is in development for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in conjunction with allogeneic hematopoietic stem cell transplantation (alloSCT). BlueSphere anticipates filing its first Investigational New Drug Application (IND) for BSB-1001 in 2023.

Presentation details:
Title: A Powerful Platform to Find TCRs to Defined Targets: Applications in Allogeneic Stem Cell Transplantation
Date: Thursday, March 2, 2023
Time: 11:30 a.m. – 12:00 p.m. PST
Location:San Diego Convention Center

For more information about the Next Generation CAR & T Cell Therapies Conference, please refer to the conference website at https://informaconnect.com/car-t/.